1H25 Business Update - Investor Presentation Materials
Released
Released
Announcement PDF
ASX Announcement
20 January 2025
1H25 Business Update – Investor Presentation Materials
Cogstate Ltd (ASX:CGS) has today provides an update in respect of financial performance for the half-year ended
31 December 2024 (1H25) based on unaudited results, including the attached investor presentation materials.
Audited 1H25 financial results will be released on Thursday, 20 February 2025.
This announcement was authorised for release by Cogstate Ltd CEO, Brad O’Connor.
| Page 1
About Cogstate
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the
development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable
and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome
assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s
clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches,
advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs
of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically
validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician
time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in the USA
& Asia. For more information, please visit www.cogstate.com.
For further information contact:
Brad O’Connor, Chief Executive Officer, boconnor@cogstate.com
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's
views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and
provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement nor any information
made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past,
present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”,
“guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking
statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking
statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and
contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors
that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general
guide only and should not be relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any
projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's
business strategies, including the that the results of any of those strategies will be realised in the period for which the forwardlooking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is
sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its
customers which are influenced by factors that are outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation,
none of Cogstate, its representatives or advisers assumes any obligation to update these forward-looking statements. No
representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking
statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or
regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide
any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future
events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are
also forward-looking statements.
| Page 2
Investor Update
20 January 2025
© 2025 Cogstate Ltd. All rights r eserved.
Disclaimer
This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general na ture and does not purport to
be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the
Corporations Act. This presentation may contain statements, opinions, projections, forecasts and other material (forward look ing statements), based on
various assumptions. Those assumptions may or may not prove to be correct. None of Cogstate, its respective officers, employe es, agents, advisers or
any other person named in this presentation makes any representation as to the accuracy or likelihood of fulfilment of any fo rward looking statements or
any of the assumptions upon which they are based.
The information contained in this presentation does not take into account the investment objectives, financial situation or p articular needs of any recipient
and is not financial product advice. Before making an investment decision, recipients of this presentation should consider th eir own needs and situation
and, if necessary, seek independent, professional advice.
To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty, repres entation or guarantee as to
the accuracy, completeness or reliability of the information contained in this presentation. Further, none of Cogstate and it s respective officers,
employees, agents and advisers accept, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in
connection with, the information contained in this presentation. Any recipient of this presentation should independently sati sfy themselves as to the
accuracy of all information contained herein.
2
Background Information
Market Cap
Shares on issue
Options on issue
Performance Rights on issue
A$180m (US$110m)
171.9m
7.6m
5.6m
Cash
Debt
US$34.2m
nil
Enterprise Value (EV)
Revenue prior 12 months
EV to Revenue multiple
US$76m
US$47m
1.6
Major shareholders:
• Dolby family (Dolby Labs, San Fran)
• Myer family (Chairman)
• Aust Ethical Investment (Sydney)
• Anacacia Capital (Sydney)
• Other Board & Management
17%
14%
10%
9%
6%
• Top 20 shareholders
81%
Current share price (at 17-Jan-25)
52 week high
52 week low
$1.110
$1.440
$0.795
3
FY25: First Half Growth
All figures in US$
1H25 based on unaudited results
1H25
2H24
1H24
Total Revenue
$23.9m
$23.3m
$20.2m
- Clinical Trials Revenue
$22.7m
$21.5m
$17.9m
- Healthcare Revenue *
$1.2m
$1.7m
$2.2m
Clinical Trials Sales Contracts Executed
$20.3m
$16.0m
$10.9m
Cash & Cash Equivalents
$34.2m
$30.1m
$25.3m
Gross Profit Margin
Consistent with 2H24
59%
54%
EBIT Margin
Consistent with 2H24
20%
9%
* Decreased Healthcare revenue reflects amended Eisai agreement announced 02 April 2024
4
Clinical Trials Revenue,
by Half Year
24
1H25
22
Clinical Trials Revenue $22.7m, up 27%
20
•
Clinical Trials revenue has returned to
growth over the last 12 months
•
1H25 result continues growth trend
from 2H24
•
Clinical Trials revenue is 95% of total
revenue
US$ Million
18
16
14
12
10
8
6
1H20
2H20
1H21
2H21
1H22
2H22
1H23
2H23
1H24
2H24
1H25
5
Clinical Trials Revenue,
by Calendar Year
50
CY24
Clinical Trials Revenue $44.2m, up 21%
45
Growth driven by:
US$ Million
40
35
30
25
•
Run-off of strong contracted revenue
backlog
•
Diversification of project type in
contracted revenue backlog (mix of
indications and phases) providing
faster revenue yield.
20
15
CY20
CY21
CY22
CY23
CY24
6
Clinical Trials Sales Contracts,
by Half Year
60
1H25
Clinical Trials Sales Contracts $20.3m
50
•
US$ Million
40
•
30
20
Alzheimer’s $14.2m
➢
1H24 $6.7m
➢
2H24 $4.1m
Other indications $6.1m
➢
1H24 $4.2m
➢
2H24 $11.9m
• Across all indications, seeing an increased
number of opportunities, reflecting:
10
➢ Expansion of Cogstate offering
0
➢ Improved funding environment for US
biotech
1H20
2H20
1H21
2H21
1H22
2H22
1H23
2H23
1H24
2H24
1H25
➢ Increased volume of opportunities via
channel partners
7
Profitable Growth
Gross Profit Margin & EBIT Margin percentages expected to be
consistent with 2H24 – the most recent half-year
•
Technology investment over the last two years continues to
drive efficiency gains across the business
•
Notwithstanding increasing revenue, the number of fulltime
employees has decreased:
➢ 154 at 31-Dec-24
➢ 161 at 30-Jun-24
➢ 166 at 31-Dec-23.
•
There have been no other significant changes to the cost
base
8
Capital Management
Cash Balance 31-Dec-24: $34.2m
Up from $30.1m at 30-Jun-24
Up from $25.3m at 31-Dec-23
Increase driven by operating cashflow
•
Receipts from Eisai under Healthcare agreement consistent over last two years
•
No capital raised, other than small number of employee share options exercised
•
No debt
New share buy-back announced 21 October 2024
•
Bought back 1,425,375 shares for total cost of A$1.6m (~ US$1.0m) during 1H25
➢ Average price of shares bought back A$1.118
•
•
5.8m shares at cost of A$8.0m bought back since Feb-2023
Buy back continuing into 2H25, subject to share trading policies and opportunity
9
Cogstate Digital Brain Health Strategy
Cogstate Strategy Overview
Market Dynamics & Cogstate Positioning
Offering
Software
• Proprietary digital assessments
• Advanced data analytic offerings for
automated quality assurance
Services
• Scientific & operational expertise
Markets
Clinical Trials
• Pharma customers
• Our established business
Healthcare
• Eisai agreement
• Our next frontier
Alzheimer’s represents generational
opportunity
Leveraging partnerships to enable
growth in other indications
Healthcare & community screening
provide growth opportunity
Market is still ripe for digital
disruption
10
Cogstate Offering In Clinical Trials
We help sponsors make decisions about their
drug candidates (“Does it work?” “Is it safe?”).
To make decisions they need conclusive, reliable
data.
We continue to develop new solutions to
minimize error in clinical outcome
assessments to help get safe and effective
drugs to market.
11
Cogstate Portfolio of 99 Ongoing Clinical Trials
Ongoing Trials,
by Indication
Ongoing Trials,
by Phase
45
9
40
35
27 Trials
30
43 Trials
4
16 Trials
25
20
15
10
Alzheimer's
Cancer, Metabolic, Healthy & Other
Mood & Other Neurological disorders
Pediatrics & Rare disease
Sleep Disorders
5
0
0
1
2
3
Phase
12
Growth Drivers: FY25 & Beyond
Cogstate growing Alzheimer’s market share
Scale through channel partnerships
• Success running important phase 3 Alzheimer’s
programs provides commercial validation
• Partnered with providers of tech to clinical trials
• We believe that industry-wide R&D spend in
Alzheimer’s will grow over the coming years
• List of partners has grown from 2 in FY23 to 5 today
Growth & diversification outside Alzheimer’s
• Partners range in size from $10m - $500m revenue
• 36% of the total number of sales opportunities came
via channel partners in 1H25
• Cogstate has expanded offering outside Alzheimer’s
over last 18 months
➢
From nominal amount in prior periods
➢
Early indication shows no decrease in win-rate
• Expanded offering has increased number of sales
opportunities with new & existing customers
➢
Cogstate margin not impacted by sale via channel
Audited Financial Results Released Thursday 20 February 2025
13
Share your feedback
Discover